[CAS NO. 1818885-28-7] ARV-825
Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis, please:
PRODUCTS SPECIFICATIONS [1818885-28-7]
Store
Catalog
SLK-S8297
Brand
Selleck
CAS
1818885-28-7
DESCRIPTION [1818885-28-7]
Overview
| MDL | MFCD29472237 |
|---|---|
| Molecular Weight | 923.43 |
| Molecular Formula | C46H47ClN8O9S |
| SMILES | CC1=NN=C2N1C(SC(C)=C3C)=C3C(C4=CC=C(Cl)C=C4)=N[C@H]2CC(NC5=CC=C(OCCOCCOCCOCCNC6=C(C(N(C7CCC(NC7=O)=O)C8=O)=O)C8=CC=C6)C=C5)=O |
For research use only.
Storage
3 years,-20°C,powder
1 years,-80°C,in solvent
1 years,-80°C,in solvent
Shipping
Room temperature shipping(Stability testing shows this product can be shipped without any cooling measures.)
Preparing Stock Solutions
| 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.0829 mL | 5.4146 mL | 10.8292 mL |
| 5 mM | 0.2166 mL | 1.0829 mL | 2.1658 mL |
| 10 mM | 0.1083 mL | 0.5415 mL | 1.0829 mL |
| 50 mM | 0.0217 mL | 0.1083 mL | 0.2166 mL |
Description
ARV-825 is a Inhibitor that recruits BRD4 to the E3 ubiquitin ligase cereblon, leading to fast, efficient, and prolonged degradation of BRD4 and sustained down-regulation of MYC.
In vitro
Compared with the BRD4 inhibitors, ARV-825 treatment results in a strikingly more pronounced effect on the levels of c-MYC, and downstream cell proliferation and apoptosis induction in BL (Burkitt’s Lymphoma) cell lines.The IC50s of ARV-825 for all tested cell lines and primary AML cells at 72 hours are in the low nanomolar range (2-50 nM). ARV-825 treatment reduces PIM1 levels and phosphorylation of CXCR4 in AML cells while overexpression of PIM1 or Myc reverses the phenomena.
References
Powered by Arctom Copyright © 2026 Arctom. All rights
reserved.